下丘脑错构瘤相关癫痫的手术治疗结局:系统评价与个体参与者数据Meta分析
该系统评价与个体参与者数据Meta分析纳入64项研究、517例下丘脑错构瘤相关癫痫患者,评估常用手术技术的安全性和有效性。末次随访时总体无发作合并比例为50.0%(95%CI 42.7%-57.4%),多次治疗后升至64.5%(95%CI 57.2%-71.5%)。磁共振引导激光间质热疗(MRgLITT)和射频热凝(RFTC)无发作率最高,立体定向放射外科(SRS)主要并发症合并比例最低(0.0%,95%CI 0.0%-1.4%)。作者认为MRgLITT和RFTC应被视为一线选择。
要点
- MRgLITT无发作率74.5%,RFTC无发作率78.5%,均高于总体水平。
- SRS主要并发症合并比例0.0%(95%CI 0.0%-1.4%),为最安全术式。
- 多种发作类型和既往手术史与较低无发作可能性独立相关。
核心结论
- MRgLITT和RFTC相比开放显微手术具有更优的有效性和安全性,应被视为一线选择。
- SRS有效性较低,但长期并发症报告少,可作为特定病例(如小体积HH且基线功能良好)的可行替代方案。
- RFTC和MRgLITT队列随访时间短限制技术间直接比较,需进一步开展大规模多中心直接比较研究。
研究设计与样本
- 系统评价与个体参与者数据Meta分析,检索PubMed、Embase和Scopus数据库,无日期限制,纳入报告1例以上患者接受手术治疗HH相关癫痫的原始研究。
- 共纳入64项研究,获得517例患者的个体参与者数据。
- 采用随机效应模型计算末次随访无发作(Engel I)的合并比例,采用混合效应逻辑回归识别无发作和主要术后并发症的预测因素。
主要发现
- 初次手术后总体无发作合并比例为50.0%(95%CI 42.7%-57.4%),多次治疗后为64.5%(95%CI 57.2%-71.5%)。
- 末次随访时MRgLITT无发作率74.5%(95%CI 66.8%-81.7%),RFTC无发作率78.5%(95%CI 71.6%-84.8%)。
- 多种发作类型与较低无发作可能性独立相关(OR 0.296,95%CI 0.140-0.624,p=0.001),既往手术史亦相关(OR 0.418,95%CI 0.198-0.884,p=0.023)。
- SRS主要并发症合并比例0.0%(95%CI 0.0%-1.4%);SRS(OR 0.024,95%CI 0.002-0.292,p=0.004)、RFTC(OR 0.133,95%CI 0.026-0.692,p=0.017)和MRgLITT(OR 0.234,95%CI 0.056-0.968,p=0.045)与较低主要并发症可能性相关。
- 总体证据质量低。
临床怎么用
- 作者认为MRgLITT和RFTC应被视为一线选择。
- 作者认为SRS可作为特定病例(如小体积HH且基线功能良好)的可行替代方案。
局限性
- 总体证据质量低。
- RFTC和MRgLITT队列随访时间短,限制技术间直接比较。
- 需进一步开展大规模多中心研究直接比较这些 modalities。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There is a paucity of data directly comparing the outcome of surgical techniques available for the treatment of hypothalamic hamartomas (HHs). This study aims to evaluate the safety and efficacy of commonly used surgical approaches in the treatment of HH-related epilepsy. METHODS: A systematic review and individual participant data (IPD) meta-analysis was conducted. The PubMed, Embase, and Scopus online databases were searched without any date restrictions for original studies with more than 1 participant reporting on patients with HH-related epilepsy who underwent surgical treatment. Random-effects modeling was used to calculate the pooled proportions of seizure freedom (Engel I) at the last follow-up. IPD were used to perform mixed-effects logistic regression to identify predictors of seizure freedom and major postoperative complications. RESULTS: Sixty-four studies were included, and IPD on 517 patients were obtained. The overall quality of evidence was low. After the index procedure, the pooled proportion of overall seizure freedom was 50.0% (95% CI 42.7%-57.4%), which increased to 64.5% (95% CI 57.2%-71.5%) after multiple treatments. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) and radiofrequency thermocoagulation (RFTC) demonstrated the highest efficacy at the last follow-up, with seizure freedom rates of 74.5% (95% CI 66.8%-81.7%) and 78.5% (95% CI 71.6%-84.8%), respectively. Factors independently associated with a lower likelihood of seizure freedom included multiple seizure types (odds ratio [OR] 0.296, 95% CI 0.140-0.624, p = 0.001) and previous surgery (OR 0.418, 95% CI 0.198-0.884, p = 0.023). Stereotactic radiosurgery (SRS) was the safest approach, with a pooled proportion of major complications of 0.0% (95% CI 0.0%-1.4%). Only surgical technique emerged as an independent predictor of major complications, with SRS (OR 0.024, 95% CI 0.002-0.292, p = 0.004), RFTC (OR 0.133, 95% CI 0.026-0.692, p = 0.017), and MRgLITT (OR 0.234, 95% CI 0.056-0.968, p = 0.045) being associated with a lower likelihood of major complications. DISCUSSION: MRgLITT and RFTC offer superior efficacy and safety compared with open microsurgery and should be considered as first-line options. Despite its lower efficacy, SRS is associated with few reported long-term complications, making it a viable alternative for select cases, such as small HHs with good baseline functioning. Direct comparisons between techniques are limited by short follow-up durations in RFTC and MRgLITT cohorts. Further large-scale, multicenter studies directly comparing these modalities are warranted.
引用
- Niazi F, Goel K, Chen JS, et al. Outcome of Surgery for Hypothalamic Hamartoma-Related Epilepsy: A Systematic Review and Individual Participant Data Meta-Analysis. Neurology. 2024. PMID: 39642321. doi:10.1212/WNL.0000000000210060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。